1. Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation 
Filippo Milano, MD, PhD, Brent L. Wood, MD, Colleen Delaney, MD, MSc 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S67-S68 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
A) Disease free survival by pretransplant MRD status. B) Disease free survival by pretransplant MRD status in patients receiving high-dose TBI (1320 CGy), cyclophosphamide and fludarabine. C) Disease free survival by pretransplant MRD status in patients receiving treosulfan, fludarabine, and a single fraction of 200CGy TBI.
Biology of Blood and Marrow Transplantation  , S67-S68DOI: ( /j.bbmt )
Copyright © Terms and Conditions